$3.5 M Gene Therapy Gets FDA Green Light | UniQure's Breakthrough in Hemophilia B Treatment

In this video, we dive into the breakthrough in hemophilia B treatment by CSL Behring and UniQure. Their transformative gene therapy, Etranacogene dezaparvovec (or EtranaDez), has received approval, offering a potential one-time treatment for this life-long condition. Priced at $3.5 million, it is one of the most expensive treatments on the market. We will discuss what this means for patients, how it compares to traditional treatment costs, and what it could mean for the future of gene therapy. Tune in to understand this medical milestone and how it could revolutionize the field. Don't forget to subscribe for the latest in health and pharma!
#Health #PharmaNews #GeneTherapy #HemophiliaB #CSLBehring #UniQure #EtranaDez #PharmaceuticalInnovation